A Phase II Trial of Perifosine (IND 58,156; NSC# 639966) in Biochemically Recurrent, Hormone Sensitive Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2015
At a glance
- Drugs Perifosine (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 22 Feb 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 07 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.